The materiality analysis identified main non-financial topic clusters and individual topics:

The materiality process

Since 2017, we have been identifying the material topics for the Fresenius Group in a comprehensive materiality analysis in accordance with the HGB. This is carried out every two to three years, depending on possible changes in the corporate structure and operating business performance. In addition, we review the material topics annually to ensure that they are up to date. Material are those aspects that are relevant for understanding Fresenius’ business performance, results of operations, and position, as well as for understanding the effects of its business activities on non-financial aspects.

Stakeholders and partnerships

Fresenius is involved in a diverse network of stakeholder groups. We gain valuable insights from this exchange which we use to continuously develop our quality and sustainability management as well as our reporting procedures. In 2019, we reviewed and prioritized our stakeholders: to this end, existing corporate communication channels, the requirements of sustainability ratings and rankings, and frequent inquiries from investors were evaluated.

Our main stakeholders are:

 

For more information on this topic see the Non-Financial Report.

 

Fresenius is committed to the Sustainable Development Goals (SDGs) of the United Nations (UN). In 2020, we therefore further explored these sustainability targets and conducted an analysis* of Fresenius' impact on the 17 SDGs. As a globally operating healthcare company, our most significant positive impact is on SDG 3 (Good Health and Well-being), SDG 4 (Quality Education), and SDG 8 (Decent Work and Economic Growth). Our analysis also identified residual risks that we will continue to address in the future as part of our sustainability management.

Our commitment to the UN Sustainable Development Goals

The UN Sustainable Development Goals are the roadmap for global sustainable development by 2030. They serve as a compass for the international community to meet the challenges within the remaining decade. To achieve this, public sector, governments and companies must pull together.

As a global health care group, Fresenius is committed to the United Nations' 17 Sustainable Development Goals. At Fresenius, the patient always comes first. For more than 100 years now we have been working to preserve life, promote health, and improve the quality of life of our patients. A clear focus on innovation and efficiency has helped us to make high-quality healthcare accessible to a steadily increasing number of people. Our business activities are thus closely linked to the concerns of the UN Sustainable Development Goals.

Fresenius operates globally in dialysis and in inpatient and outpatient care. With our products and services, we promote the health and well-being of patients worldwide. Our most important positive contribution thus relates to SDG 3 (Good Health and Well-being). The measures to promote the health of our employees and occupational health in the context of the pandemic also make positive contributions in this regard.

We also positively impact SDG 4 (Quality Education) and SDG 8 (Decent Work and Economic Growth). With our employee and social standards, as well as with various further development programs, we invest in a sustainable and healthy future: Our over 300,000 employees have access to a wide range of training and development opportunities. We are also taking steps to raise awareness of health issues among our employees and patients.

Alongside the positive effects of our business activities, our analysis also revealed a potential for improvement. If measures do not sufficiently mitigate adverse effects, residual risks remain. These relate to three SDGs in particular:

• We are making a positive contribution to SDG 9 (Industry, Innovation and Infrastructure) with the infrastructure we are creating in the healthcare sector. At the same time, we face the challenge of aligning our spending and investments even more consistently with the demands  of environmental and climate protection in the future. 

• In view of SDG 13 (Climate Action), we need to take a closer look at the physical risks of climate change and the impact on our locations.

• With regard to SDG 17 (Partnerships for the Goals), we see a future challenge in the increased demands of global tax transparency.

_{* The analysis was carried out together with Trucost, part of S&P Global https://www.trucost.com/corporate-advisory/sdg-evaluation-tool/ . This analysis evaluates the positive impact of Fresenius on the SDGs as well as the risk of negative consequences. The Trucost methodology involves a quantitative analysis of a company's SDG performance - globally and across the entire value chain. It follows a four-step process that surveys companies' risk exposure and impact using 45 metrics based on the 169 targets of the SDGs. The results were validated internally.}

(Last updated on December 2017)

We have compiled our website very carefully and it is continually expanded and updated. Nevertheless, we assume no liability for the accuracy or completeness of the contents. We do not assume any liability for direct, indirect, material or immaterial damages that may arise from the use of the information provided on this website, except when incorrect information is published intentionally or with gross negligence. Subject to the foregoing, the use of the website is at the user’s own personal risk.

For US users: Some jurisdictions may not permit certain disclaimers of warranties, so some of the exclusions above may not apply to you. In such jurisdictions, we disclaim warranties to the fullest extent permitted by applicable law.

Business information and product information

The information on this website is non-binding and intended for general information purposes only. It is not a substitute for professional financial, medical or other specialist advice. Users should not act upon this information without first seeking appropriate professional advice. Further, we are not responsible for the content of third party texts published on this website. The individual authors are responsible for their works. We do not assume any liability for damages, which arise from the use of this information.

Releases on this website may contain forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in these releases.

Rights of use

Fresenius or its affiliates are owners of all proprietor rights attaching to the web page prepared. All texts and illustrations are covered by copyright. You may take note of the information in our websites and load them into your main memory. The use of press releases as well as documents, pictures and video footage available in the media center shall be permitted solely for editorial reporting purposes. Any further reproduction or passing on to third parties shall be excluded. No rights or licenses of any kind with respect to trademarks, copyrights, patents, etc. shall be granted to the user.

Non-commitment - applicable law

It is possible that the promotion for or the procurement of individual products, services and therapies portrayed on this website is not permissible under the legal regulations valid in individual countries outside of the European Union. The web page shall not constitute a promotion of these products, services and therapies for these countries. Please note that the products displayed on this website may not be available in all countries due to different registration status. Our local subsidiaries’ websites may include different legal provisions and your use of such websites shall be subject to the provisions provided therein.
Any legal claims or lawsuits that may arise in conjunction with this website or its use are subject to the interpretation of the laws of the Federal Republic of Germany, excluding the provisions of international private law and the UN Convention on Contracts for the International Sale of Goods.

Hyperlinks

We also offer links to third-party websites in addition to our own information. The content and design of third-party websites are beyond our control. We do not ensure that the information on third-party websites is accurate or correct. The links also represent no endorsement, support or confirmation of the contents at the linked sites. The individual authors of the linked sites are responsible for the information, opinions and facts presented on their web pages. The same is true for comments made in guest books, discussion forms and e-mail lists. We are likewise not responsible for the technical security of both the links and target pages. We are therefore not liable for any damages that occur through use of either the information contained on these hyperlinks or the use of the hyperlinks themselves.

Contact and further information

© 2000 - 2017 Fresenius SE & Co. KGaA

Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172 608 0
Fax: +49 (0) 6172 608 2294
E-mail: pr-fre@fresenius.com

Published by:

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register Bad Homburg, HRB 11852
Supervisory Board: Wolfgang Kirsch (Chairman)

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser
Chairman of the Supervisory Board: Wolfgang Kirsch

Value Added Tax Identification Number (VAT ID): DE 114152311

Edited by:

Fresenius SE & Co. KGaA
Corporate Communications
61346 Bad Homburg v.d.H.
Germany
pr-fre@fresenius.com

Programming:

Fresenius Digital Technology GmbH
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H

 
This imprint is also valid for the Social Media platforms of Fresenius.

The Eugin Group, part of Fresenius Helios, acquires a majority stake in the Delaware Institute for Reproductive Medicine (DIRM), a renowned fertility center in the U.S. state of Delaware that has been established for 35 years. With this acquisition, Eugin further expands its existing network in the U.S. and expects to generate additional synergies and operational efficiencies. A number of key physicians will remain minority shareholders in DIRM. Both sides have agreed not to disclose financial details.

The Eugin Group, part of Fresenius Helios, acquires a majority stake in the Delaware Institute for Reproductive Medicine (DIRM), a renowned fertility center in the U.S. state of Delaware that has been established for 35 years. With this acquisition, Eugin further expands its existing network in the U.S. and expects to generate additional synergies and operational efficiencies. A number of key physicians will remain minority shareholders in DIRM. Both sides have agreed not to disclose financial details.

RSS feeds keep you up to speed on the latest developments within the Fresenius Group. Always in real time and directly on your computer or mobile device.

Fresenius offers you two different RSS feeds:

 

RSS feed Investor News

RSS feed Press Releases

 

Furthermore, you can find additional RSS feeds with job openings on our career website.

 

You can read RSS feeds using an RSS-enabled Web browser. Alternatively, there are special programs called feed readers.

 

For more information on RSS, please consult i. e. Wikipedia.

Here you can download our Privacy Notice for the use of Microsoft 365 Services